The share price of Oklo Inc. (NYSE:OKLO) surged by 23.04% on May 23, 2025. Let’s shed some light on the development. Backed ...

N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...